- Preparing For Appointments
- Contact Us
- Maps and Directions
- Clinical Trials
- Our Physicians
- Frequently Asked Questions
Events & Groups:
Join Us On Facebook.
Follow us on Twitter.
Clearview News Wire
Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Top court rejects Pfizer punitive damages appeal
June 22, 2010
Top court rejects Pfizer punitive damages appealLast Updated: 2010-06-21 13:00:24 -0400 (Reuters Health)
WASHINGTON (Reuters) - The Supreme Court rejected Pfizer Inc's appeal of a ruling that ordered a retrial on how much punitive damages should be awarded to a woman who developed breast cancer after taking the company's hormone replacement therapy drugs.
Pfizer in its appeal argued that a retrial limited to just punitive damages had violated its constitutional right to a jury trial and that the trial judge in the case had improperly admitted the testimony of a scientific expert.
An Arkansas jury in 2008 sided with Donna Scroggin in her lawsuit against two Pfizer units - Wyeth and Upjohn. She was diagnosed with breast cancer in 2000, after taking hormone replacement therapy drugs for 11 years.
The jury awarded her compensatory damages of $2.7 million and punitive damages of $19.4 million against Wyeth and $7.8 million against Upjohn.
A U.S. appeals court upheld the jury's award of compensatory damages and said a federal judge had correctly set aside the punitive damages award against Upjohn as a matter of law. The appeals court ordered a new trial on punitive damages involving Wyeth.
Pfizer in its appeal opposed a partial retrial limited to punitive damages, saying it would lead to confusion and uncertainty for the jury and would be a denial of its right to a fair trial.
The pharmaceutical company and legal groups supporting it said the appeals court should have ordered an entirely new trial.
On Monday, the Supreme Court rejected the company's appeal without any comment
In 2002, the National Institutes of Health published the results of its study that linked the use of hormone replacement therapy to breast cancer.
Last Updated: 2010-06-21 13:00:24 -0400 (Reuters Health)
WASHINGTON (Reuters) - The Supreme Court rejected Pfizer Inc's appeal of a ruling that ordered a retrial on how much punitive damages should be awarded to a woman who developed breast cancer after taking the company's hormone replacement therapy drugs.
Pfizer in its appeal argued that a retrial limited to just punitive damages had violated its constitutional right to a jury trial and that the trial judge in the case had improperly admitted the testimony of a scientific expert.
An Arkansas jury in 2008 sided with Donna Scroggin in her lawsuit against two Pfizer units - Wyeth and Upjohn. She was diagnosed with breast cancer in 2000, after taking hormone replacement therapy drugs for 11 years.
The jury awarded her compensatory damages of $2.7 million and punitive damages of $19.4 million against Wyeth and $7.8 million against Upjohn.
A U.S. appeals court upheld the jury's award of compensatory damages and said a federal judge had correctly set aside the punitive damages award against Upjohn as a matter of law. The appeals court ordered a new trial on punitive damages involving Wyeth.
Pfizer in its appeal opposed a partial retrial limited to punitive damages, saying it would lead to confusion and uncertainty for the jury and would be a denial of its right to a fair trial.
The pharmaceutical company and legal groups supporting it said the appeals court should have ordered an entirely new trial.
On Monday, the Supreme Court rejected the company's appeal without any comment
In 2002, the National Institutes of Health published the results of its study that linked the use of hormone replacement therapy to breast cancer.
Tweet
Other Articles:
- September 1, 2010
- More evidence hormone therapy can muddy mammograms
- August 31, 2010
- Prostate biopsy can cause urinary, erectile problems
- August 26, 2010
- Some men may get too many PSA tests: study
- August 24, 2010
- Ob/gyn group backs HPV vaccines for 11-12 year olds
- August 23, 2010
- Men with high CRP have higher risk of colon cancer
- August 20, 2010
- Developing nations to bear cancer brunt, unprepared
- August 19, 2010
- Race, ethnicity, other factors delay chemo after breast cancer surgery
- August 18, 2010
- Doctors discover tumor in Michael Douglas' throat
- August 16, 2010
- Personality not linked to cancer risk or prognosis
- August 13, 2010
- Cancer gets first TV comedy twist in "The Big C"
- August 9, 2010
- Avastin (bevacizumab) gives best lung cancer survival rate
- August 4, 2010
- Mediterranean diet tied to lower breast cancer risk
- August 3, 2010
- Cancer cells thrive on fructose, US study finds
- August 3, 2010
- Chemicals in meat may be linked to bladder cancer
- July 27, 2010
- Low-risk prostate cancer treated aggressively
- July 22, 2010
- California city approves marijuana farming
- July 22, 2010
- No Pap smears for women under 21: guidelines
- July 21, 2010
- Darker skin doesn't mean melanoma immunity
- July 21, 2010
- New study backs Avastin in lung cancer
- July 19, 2010
- Americans turn cold shoulder to sunscreen: poll
- July 19, 2010
- Lung cancer often recurs more than 5 years after resection
- July 16, 2010
- U.S. cancer group endorses newer breast cancer drugs
- July 15, 2010
- Palliative care lacking in much of the world
- July 12, 2010
- Fish oil might lower breast cancer risk
- July 12, 2010
- Study finds prostate screening cuts cancer deaths